



## Immunogenic Effects of Electroporation-Based Treatments

Guest Editors:

**Prof. Dr. Emanuela Signori**

**Prof. Dr. Maja Čemažar**

**Prof. Mariangela De Robertis**

**Prof. Loreé C. Heller**

**Prof. Dr. Richard Heller**

Deadline for manuscript  
submissions:  
**closed (31 March 2023)**

### Message from the Guest Editors

Studies in the field of immunology are revealing an attractive set of novel and different therapeutic approaches to treat cancer and infectious diseases. Electroporation, also named electropermeabilization (EP), is an efficient and safe technique based on the application of voltage pulses of sufficient strength and duration to generate transient membrane permeabilization/poration, thus allowing the delivery of drugs or genetic material into the target cells via electrotransfer. Following EP treatments, different innate and adaptive immune cells can be recruited, influencing immune responses at local and distant levels. Due to this property, many studies in the field of immunization by electroporation have been undertaken.

In this Special Issue, induction of immunological effects and enhancement of the immune system response induced by genetic vaccines and/or immunomodulatory molecules, administered alone or in combination with other therapeutic treatments by EP, will be discussed. Presentations of results on the immunological effects of drugs delivered by electric fields in pre-clinical and clinical trials will be very welcome as well.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)